1 **Characteristics and outcomes of hospitalized adult COVID-19 patients in Georgia**

2 Tengiz Tsertsvadze, MD, PhD,^{1,2} Marina Ezugbaia, MD,¹ Marina Endeladze, MD,¹ Levani
3 Ratiani MD, PhD,³ Neli Javakhishvili MD,⁴ Lika Mumladze MD,⁵ Manana Khotchava MD,
4 PhD,⁶ Maiko Janashia MD,⁷ Diana Zviadadze MD,⁸ Levan Gopodze MD,⁹ Alex Gokhelashvili
5 MD,¹⁰ Revaz Metchurchtlishvili, MD,¹ Akaki Abutidze, MD, MPH, PhD,^{1,2} Nikoloz
6 Chkhartishvili, MD, MS, PhD^{1,11}

7
8 ¹Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

9 ²Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia

10 ³First University Clinic, Tbilisi, Georgia

11 ⁴Giorgi Abramishvili Military Hospital, Gori, Georgia

12 ⁵St. King Mirian and Queen Nana Mtskheta Regional Medical Center, Georgia

13 ⁶Children's Infectious Diseases Hospital, Tbilisi, Georgia

14 ⁷University Clinic Rukhi, Georgia

15 ⁸LJ Clinic Kutaisi, Georgia

16 ⁹Central Republican Hospital, Tbilisi, Georgia

17 ¹⁰Medalpha Clinic, Batumi, Georgia

18 ¹¹Caucasus International University, Tbilisi, Georgia

19
20 Corresponding author: Tengiz Tsertsvadze, MD, PhD

21 16 Al Akzbezi Avenue, Tbilisi 0160, Georgia

22 Telephone: (995 32) 23999922, Fax: (995 32) 2399144

23 Email: tt@aidscenter.ge

Abstract

Objective: Describe presenting characteristics of hospitalized patients and explore factors associated with in-hospital mortality during the first wave of pandemic in Georgia.

Methods: This retrospective study included 582 adult patients admitted to 9 dedicated COVID-19 hospitals as of July 30, 2020 (72% of all hospitalizations). Data were abstracted from medical charts. Factors associated with mortality were evaluated in multivariable Poisson regression analysis.

Results: Among 582 adults included in this analysis 14.9% were 65+ years old, 49.1% were women, 59.3% had uni- or bi-lateral lung involvement on chest computed tomography, 27.1% had any co-morbidity, 13.2% patients had lymphopenia, 4.1% had neutrophilosis, 4.8% had low platelet count, 37.6% had d-dimer levels of >0.5 mcg/l. Overall mortality was 2.1% (12/582). After excluding mild infections, mortality among patients with moderate-to-critical disease was 3.0% (12/399), while among patients with severe-to-critical disease mortality was 12.7% (8/63). Baseline characteristics associated with increased risk of mortality in multivariate regression analysis included: age ≥ 65 years (RR: 10.38, 95% CI: 1.30-82.75), presence of any chronic co-morbidity (RR: 20.71, 95% CI: 1.58-270.99), lymphopenia (RR: 4.76, 95% CI: 1.52-14.93), neutrophilosis (RR: 7.22, 95% CI: 1.27-41.12), low platelet count (RR: 6.92, 95% CI: 1.18-40.54), elevated d-dimer (RR: 4.45, 95% CI: 1.48-13.35), elevated AST (RR: 6.33, 95% CI: 1.18-33.98).

Conclusion: In-hospital mortality during the first wave of pandemic in Georgia was low. We identified several risk factors (older age, co-morbidities and laboratory abnormalities) associated with poor outcome that should provide guidance for planning health sector response as pandemic continues to evolve.

Introduction

Ongoing pandemic of novel coronavirus disease 2019 (COVID-19) showed differential impact on mortality across the European continent, with cumulative mortality ranging from 1 to over 100 death per 100,000 population (1). Georgia is a small Eastern European country that rapidly responded to the pandemic threat by implementing effective public health and clinical measures achieving one of the lowest mortality rates of 1.25 per 100,000 population as of October 5, 2020 (1). The care pathway model included testing with real-time reverse transcriptase polymerase chain reaction (RT-PCR) of suspected cases (contacts of confirmed cases, persons with symptoms suggestive of COVID-19) with rapid hospitalization of all confirmed cases regardless of disease severity. Sixteen “fever” centres have been established for initial triage and RT-PCR diagnostics of symptomatic persons, while in-patient care was provided in 12 dedicated COVID-19 hospitals. The objective of this study was to describe presenting characteristics of hospitalized patients and explore factors associated with in-hospital mortality during the first wave of pandemic.

Methods

This retrospective study included unselected consecutive patients with RT-PCR confirmed COVID-19 admitted to 9 designated COVID-19 hospitals across the country between February 26 and July 30, 2020, for whom complete outcome data was known (discharged alive or died in hospital).

As of July 30, 2020, 1160 persons with confirmed COVID-19 have been hospitalized in Georgia, among them outcome was available for 952 patients of whom 935 (98.2%) were discharged alive and 17 (1.8%) died. For present analysis complete outcome was available for 678 hospitalized persons (582 adults and 96 children) of whom 666 (98.2%) were discharged alive and 12 (1.8%) died. All lethal outcomes were registered among adults and therefore analysis was limited to persons aged ≥ 18 years.

Data were extracted from medical charts, including demographic characteristics, symptoms at presentation, vital signs, laboratory assays, presence of chronic co-morbid conditions, complications during hospital stay, admission to intensive care unit (ICU), need for oxygen support, treatment strategy and outcome of hospitalization. Treatment is provided in accordance with the national protocols, which is the “living guideline” regularly updated with emerging evidence. Confirmed cases were classified into mild, moderate, severe and critical disease.

Results

Among 582 adults included in this analysis the median age was 46 (IQR: 34-58) years, 14.9% were 65+ years old, 49.1% were women. At the time of hospitalization 13.1% patients had no symptoms, 59.3% had uni- or bi-lateral lung involvement on chest CT and 27.1% patients had any chronic co-morbid condition (cardiovascular disease, diabetes, cancer, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease). With regard to baseline laboratory values 13.2% patients had lymphopenia, 4.1% had neutrophilosis, 4.8% thrombocytopenia, 37.6% had d-dimer levels of >0.5 mcg/l, 14.8% patients had AST levels >40 IU/l and 14.3% had creatinine levels of >100 mcmol/l. Based on baseline characteristics 183 (31.4%) patients were classified as having mild disease, 336 (57.7%) – moderate disease, 53 (9.1%) – severe disease and 10 (1.7%) –critical disease.

Over the median length of stay of 20 (IQR: 16-24) days 12 adult died with mortality of 2.1%. Baseline characteristics associated with increased risk of mortality in multivariate regression analysis included: age ≥ 65 years (RR: 10.38, 95% CI: 1.30-82.75), presence of any chronic co-morbidity (RR: 20.71, 95% CI: 1.58-270.99), lymphocyte count $<1 \times 10^9/l$ (RR: 4.76, 95% CI: 1.52-14.93), neutrophil count $>8 \times 10^9/l$ (RR: 7.22, 95% CI: 1.27-41.12), platelet count $<150 \times 10^9/l$ (RR: 6.92, 95% CI: 1.18-40.54), d-dimer >0.5 mcg/ml (RR: 4.45, 95% CI: 1.48-13.35), AST >40 IU/l (RR: 6.33, 95% CI: 1.18-33.98) (Table 1).

Mortality rates by severity of disease at presentation were: 0.0% (0/183) for mild disease, 1.2% (4/336) for moderate, 3.8% (2/53) for severe disease and 60% (6/10) for critical disease (Table

2). After excluding mild infections, mortality among patients with moderate-to-critical disease was 3.0% (12/399), while among patients with severe-to-critical disease mortality was 12.7% (8/63).

A total of 91 (15.6%) patients developed complications during hospital stay, including 25 (4.3%) patients developing multiple complications resulting in 11 deaths. Spectrum of complications included 43 (7.4%) new episodes of pneumonia, 19 (3.3%) acute respiratory distress syndrome, 6 (1.0%) cardiovascular events (3 acute coronary disease, 2 ischemic strokes, 1 haemorrhagic stroke), 19 (3.3%) sepsis/septic shock, 6 (1.0%) acute liver injury, 10 (1.7%) acute kidney injury, 19 (3.3%) cytokine storm (Table 2). Forty-one (7.0%) patients required admission to ICU resulting in 12 deaths (29.3% mortality) and 44 (7.6%) patients required oxygen support resulting in 12 deaths (27.3% mortality) (Table 2).

Overall 282 (48.5%) patient received standard of care treatment only, 291 (50.0%) received hydroxychloroquine and 9 (4.8%) - lopinavir/ritonavir. In addition, 338 (58.1%) patients received antibiotics, 52 (8.9%) – corticosteroids, 2 (0.3%) - tocilizumab, 3 (0.5%) – plasmapheresis, 3 (0.5%) blood purification with cytosrobents and 2 (0.3%) transfusion of convalescent plasma.

Discussion

In this cohort of consecutive hospitalized adult patients with laboratory confirmed COVID-19 we found low in-hospital mortality of 2.1% among total population, 3% - among patients with at least moderate disease and 12.7% among patient with at least severe disease at presentation.

Overall mortality shown in our study is lower than 18.88% reported in recent meta-analysis, even if we limit our analysis to patients with severe/critical disease (2). However, the difference needs to be interpreted with caution in light of varying criteria for hospitalization and rationing of resources in overburdened healthcare systems (3). Reported rates of mortality among patients admitted to ICU or requiring ventilation ranges between 23% and 53% (4-7), with our study showing mortality of 29.3%.

Similar to other studies older age, presence of chronic comorbidities and laboratory abnormalities (leukopenia, neutrophilosis, thromocytopenia and increase in d-dimer) have been significantly associated with mortality (8-11). Interestingly, our data did not show gender-based differences neither in univariate nor multivariate analysis., while reports from other countries universally indicate increased risk of death among men (12).

Predicting outcomes of COVID_19 disease has been a subject of intensive research (13). This is particularly important for Georgia as the country moved from hospitalize all approach to outpatient care of persons with mild disease because of significant increase in diagnosis since September 2020 (1). Defining criteria for hospitalization is crucial for appropriate utilization of healthcare resources without compromising lives. In our study baseline clinical characteristics,

such as fever, abnormalities in respiratory rate, oxygen saturation and chest CT imaging showed significant association with mortality only in univariate analysis. As an example, 4 patients in our cohort, initially classified to have moderate disease, had significant deterioration of their condition leading to death. All these 4 patients had pre-existing cardiovascular disease, 3 had elevated d-dimer along with lymphopenia – combination of factors that had been shown to predict progression of disease (14). This suggests that initial clinical presentation may not be sufficient for predicting outcome, it is rather complex issue that requires combinations of several determinants, including laboratory parameters.

Our analysis included 72% of COVID-19 hospitalizations occurring in Georgia during the first wave of pandemic thus ensuring representativeness of national data. Limitations include small sample size and small number of events that affected statistical power. Analysis was limited to laboratory parameters included in basic package of care, while other biomarkers known to be associated with outcome such as albumin, IL-6, ferritin (15), were available only for small subset of patients.

In summary, in-hospital mortality during the first wave of pandemic in Georgia was low. Our study characterized risk factors (older age, co-morbidities and laboratory abnormalities) associated with poor outcome that should provide guidance for planning health sector response as pandemic continues to evolve.

References

1. European Centre for Disease Prevention and Control. Situation dashboard - COVID-19 cases in Europe and worldwide. Stockholm: ECDC; 2020 [cited 2020 October 5]; Available from: <https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html>.
2. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health. 2020.
3. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med. 2020 May 21;382(21):2049-55.
4. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020:m1996.
5. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020:m1985.
6. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020 Apr 28;323(16):1574-81.
7. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Resp Med. 2020;8(9):853-62.

- 207 8. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V,
208 Fácila L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis
209 With 611,583 Subjects. *J Am Med Dir Assoc*. 2020;21(7):915-8.
- 210 9. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
211 associated with mortality in 31,461 adults with COVID-19 in the United States: A federated
212 electronic medical record analysis. *PLoS Med*. 2020 Sep;17(9):e1003321.
- 213 10. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients
214 with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. *European*
215 *Journal of Internal Medicine*. 2020;76:97-9.
- 216 11. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to
217 predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost*. 2020;18(6):1324-
218 9.
- 219 12. Haitao T, Vermunt JV, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, et al.
220 COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clin Proc*. 2020
221 Oct;95(10):2189-203.
- 222 13. Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, et al.
223 Systematic evaluation and external validation of 22 prognostic models among hospitalised adults
224 with COVID-19: An observational cohort study. *Eur Respir J*. 2020 Sep 25.
- 225 14. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease
226 progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. *Nature*
227 *Communications*. 2020;11(1).
- 228 15. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical
229 and immune biomarker abnormalities associated with severe illness and mortality in coronavirus

disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine
(CCLM). 2020;58(7):1021-8.

Table 1. Baseline characteristic of study population and factors associated with mortality (n=582)

	Total, n (%)	Died, n (%)	Univariate analysis		Multivariate analysis	
			RR (95% CI)	p value	RR (95% CI)	p value
Age categories						
18-65	495 (85.1)	2 (0.4)	1		1	
65+	87 (14.9)	10 (11.5)	28.45 (6.34-127.63)	<0.0001	10.38 (1.30-82.75)	0.03
Gender						
Female	286 (49.1)	7 (2.4)	1		1	
Male	296 (50.9)	5 (1.7)	0.69 (0.22-2.15)	0.52	1.82 (0.47-7.08)	0.38
Symptoms other than fever						
Asymptomatic	76 (13.1)	1 (1.3)	1		1	
Symptomatic	506 (97.8)	11 (2.2)	1.65 (0.21-12.62)	0.63	0.17 (0.01-4.23)	0.28
Temperature						
<37	252 (43.3)	4 (1.6)	1		1	
37-<38	271 (46.6)	4 (1.5)	0.93 (0.24-3.68)	0.92	0.27 (0.06-1.16)	0.08
38+	59 (10.1)	4 (6.8)	4.27 (1.10-16.59)	0.04	0.25 (0.06-1.17)	0.08
Respiratory rate						
<24	520 (89.3)	4 (0.8)	1		1	
24+	62 (10.7)	8 (12.9)	16.78 (5.20-54.10)	<0.0001	1.90 (0.25-14.58)	0.53
Oxygen saturation						
≥94	530 (91.1)	6 (1.1)	1		1	
<94	52 (8.9)	6 (11.5)	10.19 (3.41-30.47)	<0.0001	1.69 (0.37-7.75)	0.50
Chest CT						
No lung involvement	237 (40.7)	1 (0.4)	1		1	
Uni- or Bi-lateral involvement	345 (59.3)	11 (3.19)	7.56 (0.98-58.14)	0.05	1.51 (0.09-24.62)	0.77
Comorbidities						
No comorbidities	424 (72.9)	1 (0.2)	1		1	
Any comorbidity	158 (27.1)	11 (7.0)	29.52 (3.84-226.78)	0.001	21.15 (1.60-280.56)	0.02

BMI						
<25	238 (40.9)	5 (2.1)	1		1	
25-30	283 (48.6)	4 (1.4)	0.67 (0.18-2.48)	0.55	0.19 (0.02-1.48)	0.11
>30	61 (10.5)	3 (4.9)	2.34 (0.58-9.53)	0.23	1.50 (0.29-7.88)	0.63
Hemoglobin						
≥12 g/dl	521 (89.5)	8 (1.5)	1		1	
<12 g/dl	61 (10.5)	4 (6.6)	4.27 (1.32-13.77)	0.02	1.67 (0.54-5.14)	0.37
White blood count						
≤11 X 10 ⁹ /l	564 (96.9)	9 (1.6)	1		1	
>11 X 10 ⁹ /l	18 (3.1)	3 (16.7)	10.44 (3.09-35.36)	0.002	3.29 (0.31-35.26)	0.33
Lymphocyte count						
≥1 X 10 ⁹ /l	505 (86.8)	6 (1.2)	1		1	
<1 X 10 ⁹ /l	77 (13.2)	6 (7.8)	6.56 (2.17-19.82)	0.0009	4.74 (1.48-15.10)	0.008
Neutrophil count						
≤8 X 10 ⁹ /l	558 (95.9)	9 (1.6)	1		1	
>8 X 10 ⁹ /l	24 (4.1)	3 (12.5)	7.75 (2.24-26.81)	0.001	7.27 (1.26-41.89)	0.03
Platelet count						
≥150 X 10 ⁹ /l	553 (95.2)	10 (1.8)	1		1	
<150 X 10 ⁹ /l	28 (4.8)	2 (7.1)	3.94 (0.91-17.18)	0.07	6.99 (1.20-40.61)	0.03
D-dimer						
≤0.5 mcg/ml	363 (62.4)	2 (0.6)	1		1	
>0.5 mcg/ml	219 (37.6)	10 (4.6)	8.29 (1.83-37.48)	0.006	4.47 (1.51-13.24)	0.007
C reactive protein						
≤5 mg/l	214 (36.8)	2 (0.9)	1		1	
>5 mg/l	368 (63.2)	10 (2.7)	2.91 (0.64-13.15)	0.17	1.26 (0.17-9.51)	0.82
ALT						
≤40 IU/l	468 (80.4)	9 (1.9)	1		1	
>40 IU/l	114 (19.6)	3 (2.6)	1.37 (0.38-4.97)	0.63	4.54 (0.77-26.93)	0.10

AST						
≤40 IU/l	496 (85.2)	7 (1.4)	1		1	
>40 IU/l	86 (14.8)	5 (5.8)	4.12 (1.34-12.68)	0.01	6.34 (1.18-34.13)	0.03
Creatinine						
≤100 mcmol/l	499 (85.7)	8 (1.6)	1		1	
>100 mcmol/l	83 (14.3)	4 (4.8)	3.01 (0.93-9.76)	0.07	1.88 (0.56-6.31)	0.31

255 **Table 2. Mortality by severity of disease and complications during hospital stay (n=582)**

	Total (n=582)	Discharged alive (n=570)	Died (n=12)	p value
Severity of disease at baseline, n (%)				
Mild	183 (31.4)	183 (100.0)	0 (0.0)	0.0007
Moderate	336 (57.7)	332 (98.8)	4 (1.2)	
Severe	53 (9.1)	51 (96.2)	2 (3.8)	
Critical	10 (1.7)	4 (40.0)	6 (60.0)	
Complications during hospital stay, n (%)				
None	491 (84.4)	491 (100.0)	0 (0.0)	<0.0001
1 complication	66 (11.3)	65 (98.5)	1 (1.5)	
>1 complication	25 (4.3)	14 (56.0)	11 (44.0)	
Pneumonia, n (%)				
No	539 (92.6)	528 (98.0)	11 (2.0)	0.61
Yes	43 (7.4)	42 (97.7)	1 (2.3)	
ARDS, n (%)				
No	554 (95.2)	552 (99.6)	2 (0.4)	<0.0001
Yes	28 (4.8)	18 (64.3)	10 (35.7)	
Cardiovascular events, n (%)				
None	576 (99.0)	568 (98.6)	8 (1.4)	<0.0001
Acute coronary disease	3 (0.5)	0 (0.0)	3 (100.0)	
Ischemic stroke	2 (0.3)	2 (100.0)	0 (0.0)	
Hemorrhagic stroke	1 (0.2)	0 (0.0)	1 (100.0)	
Sepsis/septic shock, n (%)				
No	563 (96.7)	562 (99.8)	1 (0.2)	<0.0001
Yes	19 (3.3)	8 (42.1)	11 (57.9)	
Acute liver injury, n (%)				
No	576 (99.0)	565 (98.1)	11 (1.9)	0.11
Yes	6 (1.0)	5 (83.3)	1 (16.7)	
Acute kidney injury, n (%)				
No	572 (98.3)	565 (98.8)	1 (1.2)	<0.0001
Yes	10 (1.7)	5 (50.0)	1 (50.0)	
Cytokine storm, n (%)				
No	563 (96.7)	554 (98.4)	9 (1.6)	0.005
Yes	19 (3.3)	16 (84.2)	3 (15.8)	
Admission to ICU, n (%)				
No	541 (93.0)	541 (100.0)	0 (0.0)	<0.0001
Yes	41 (7.0)	29 (70.7)	12 (29.3)	
Oxygen support, n (%)				
No oxygen support	538 (92.4)	538 (100.0)	0 (0.0)	<0.0001
Oxygen support, n (%)	44 (7.6)	32 (72.7)	12 (27.3)	